Subscribe to our Email Alerts

$12.4m Capital Raise


Today, Amplia has announced a $12.4million capital raising via Placement and Entitlement offer.

Proceeds from this capital raise are forecast to fund Amplia’s plans to conduct a Phase 2 clinical trial of AMP945 in patients with pancreatic cancer, including:

  • Initiation of a dose selection study and initial assessment of efficacy of AMP945 combined with gemcitabine/Abraxane standard of care in pancreatic cancer patients;

  • Additional manufacturing work to provide clinical grade AMP945, at scale; 
  • Further preclinical studies of FAK inhibitors AMP945 and AMP886;

  • Working capital for the advancement of corporate and business development activities.

Click here to read today’s ASX release.

Click here to view the Investor Presentation.